INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN2m ago
Public company

BLSMBlossomHill Therapeutics, Inc.

CIK 0001839970

EDGAR filingsOpen in network
Disclosed transactions25
Buys / sells3 / 0
Max Insider Score46
Connections7with evidence

BLSM · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
LP
Liptak Vincent PaulGeneral Counsel
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
46.6K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Liptak Vincent PaulGeneral Counsel · Aug 10, 2026
  • ← Insider ofevidence
    Agrawal SundeepDirector · Aug 10, 2026
  • ← Insider ofevidence
    Oxnard Geoffrey RaymondChief Medical Officer · Aug 10, 2026
5
LP
Liptak Vincent PaulGeneral Counsel
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C
—
22.7K sh
Aug 10, 2026
Aug 10, 2026
traded Aug 10, 2026
+0d
SEC FORM 4

Evidence

9
OR
Oxnard Geoffrey RaymondChief Medical Officer
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
61.8K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

34
LP
Liptak Vincent PaulGeneral Counsel
BLSMBlossomHill Therapeutics, Inc.
Open-market purchase
BUY$40K
2,500 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

5
LP
Liptak Vincent PaulGeneral Counsel
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
22.7K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
AS
Agrawal SundeepDirector
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
578.5K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

13
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
113.4K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

13
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
113.4K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
112.7K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
113.4K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

30
LP
Liptak Vincent PaulGeneral Counsel
BLSMBlossomHill Therapeutics, Inc.
Open-market purchase
BUY$35K
2,200 sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
AS
Agrawal SundeepDirector
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
23.9K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

9
AS
Agrawal SundeepDirector
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
578.5K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
676.2K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
113.4K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
CJ
Cui Jingrong JeanDirector, President and CEO, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

46
KA
Keyes Jason AChief Financial Officer
BLSMBlossomHill Therapeutics, Inc.
Open-market purchase
BUY$11K
700 sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
KA
Keyes Jason AChief Financial Officer
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
56.7K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Li YishanDirector, Executive Chairman, 10% Owner · Aug 10, 2026
  • ← Insider ofevidence
    Keyes Jason AChief Financial Officer · Aug 10, 2026
  • ← Insider ofevidence
    Cui Jingrong JeanDirector, President and CEO, 10% Owner · Aug 10, 2026